Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088813 · ClinicalTrials.gov registry record · Phase 3
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
A Phase 3 study of Small-cell Lung Cancer, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
- 20
- Study locations
NCT03088813 is a Phase 3 study of Small-cell Lung Cancer that has completed, run by Ipsen. The registered enrollment target is 491 participants, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (117% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03088813, a Phase 3 study of Small-cell Lung Cancer, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy The study was conducted in two parts: 1. Dose determination of irinotecan liposome injection 2. A randomized, efficacy study of irinotecan liposome injection versus topotecan
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG Irinotecan liposome injection
Study Locations (20)
Michigan
- Henry Ford Hospital - Detroit
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
- Sparrow Regional Cancer Center - Lansing
Colorado
- National Jewish Health - Denver
- Rocky Mountain Cancer Centers - Denver
Florida
- Florida Cancer Specialists (South Region) - Fort Myers
- Florida Cancer Specialists - St. Petersburg
Georgia
- Northwest Georgia Oncology Centers - Marietta
- Cancer Treatment Centers of America-Georgia - Newnan
New York
- Roswell Park Cancer Institute - Buffalo
- North Shore Hematology Oncology Associates, PC - East Setauket
Ohio
- Case Western Reserve University - Cleveland
- Tri County Hematology & Oncology Associates, Inc - Massillon
South Carolina
- Charleston Hematology Oncology Associates, PA - Charleston
- Greenville Hospital System University Medical Center - Greenville
Illinois
- Illinois Cancer Care, PC - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088813
The ClinicalTrials.gov registry entry for NCT03088813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (117% higher). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Topotecan is the first listed.
NCT03088813 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Michigan, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03088813 about?
NCT03088813 is a clinical study titled "Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer". A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy The study was conducted in two parts: 1. Dose determination of irinotecan liposome injection...
What is the current status of trial NCT03088813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 2018-04-25. Estimated completion is 2023-07-27.
What conditions does trial NCT03088813 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03088813?
The interventions under investigation include: Topotecan (DRUG), Irinotecan liposome injection (DRUG).
Who is sponsoring clinical trial NCT03088813?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03088813 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.